IQVIA (NYSE:IQV) Shares Sold Off by Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold $15,001–$50,000 of IQVIA shares on September 14 through the HERN FAMILY FOUNDATION account, alongside sales of several other stocks.
• IQVIA reported quarterly EPS of $3.15, exceeding the $3.03 consensus estimate, while revenue rose 8.7% year over year to $4.37 billion. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• Analysts maintain a “Moderate Buy” consensus rating with a $253.25 average price target, although IQVIA insiders sold 15,581 shares worth approximately $3.8 million during the past quarter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. NYSE: IQV. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in IQVIA stock on September 14th. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Devon Energy NYSE: DVN on 9/14/2026.

IQVIA Price Performance

Shares of IQV opened at $271.01 on Tuesday. The company has a market capitalization of $44.61 billion, a price-to-earnings ratio of 33.62, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $277.40. The firm has a 50-day simple moving average of $250.32 and a 200-day simple moving average of $203.63. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.56 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of several research analyst reports. William Blair upgraded shares of IQVIA to a "strong-buy" rating in a research report on Tuesday, July 28th. Morgan Stanley raised their price objective on shares of IQVIA from $240.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday, September 17th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. HSBC reaffirmed a "buy" rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Finally, Wall Street Zen raised IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, September 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $253.25.

Insider Activity at IQVIA

In other news, insider Bhavik Patel sold 1,855 shares of the business's stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,581 shares of company stock worth $3,796,021 over the last quarter. 1.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

Institutional investors have recently modified their holdings of the company. Apella Capital LLC boosted its holdings in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company's stock valued at $211,000 after acquiring an additional 58 shares in the last quarter. Breakwater Capital Group boosted its position in IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company's stock worth $401,000 after acquiring an additional 64 shares during the period. First Growth Capital LLC grew its position in IQVIA by 3.2% during the first quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company's stock valued at $375,000 after purchasing an additional 68 shares in the last quarter. Root Financial Partners LLC grew its holdings in shares of IQVIA by 31.0% during the 4th quarter. Root Financial Partners LLC now owns 296 shares of the medical research company's stock valued at $67,000 after acquiring an additional 70 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its position in IQVIA by 1.5% in the 1st quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company's stock worth $812,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.